Cytori Therapeutics - WACC Analysis

Cytori Therapeutics (Weighted Average Cost of Capital (WACC) Analysis)

placeholder_large_analysis.png

Banner%20-%20The%20perfect%20tool%20for%20investors%281%29.gif

Helpful Information for Cytori Therapeutics's Analysis

What is the WACC Formula? Analyst use the WACC Discount Rate (weighted average cost of capital) to determine Cytori Therapeutics's investment risk. WACC Formula = Cost of Equity (CAPM) * Common Equity + (Cost of Debt) * Total Debt. The result of this calculation is an essential input for the discounted cash flow (DCF) analysis for Cytori Therapeutics. Value Investing Importance? This method is widely used by investment professionals to determine the correct price for investments in Cytori Therapeutics before they make value investing decisions. This WACC analysis is used in Cytori Therapeutics's discounted cash flow (DCF) valuation and see how the WACC calculation affect's Cytori Therapeutics's company valuation.

WACC Analysis Information

1. The WACC (discount rate) calculation for Cytori Therapeutics uses comparable companies to produce a single WACC (discount rate). An industry average WACC (discount rate) is the most accurate for Cytori Therapeutics over the long term. If there are any short-term differences between the industry WACC and Cytori Therapeutics's WACC (discount rate), then Cytori Therapeutics is more likely to revert to the industry WACC (discount rate) over the long term.

2. The WACC calculation uses the higher of Cytori Therapeutics's WACC or the risk free rate, because no investment can have a cost of capital that is better than risk free. This situation may occur if the beta is negative and Cytori Therapeutics uses a significant proportion of equity capital.